Biomarkers of Molecular Risk in Smokers
This study consists of two arms; both of which are observational studies of molecular
assessments of risk for tobacco related cancer. Arm A of the protocol is a pilot
crosssectional study that evaluates the feasibility of obtaining and testing a genetic
marker of cancer susceptibility (UGT1A7 polymorphisms) in smokers. It also explores smokers'
interest in and comprehension of genetic risk assessments as possible tools for increasing
motivation for smoking cessation. The second arm of this protocol, Arm B, is an
observational prospective evaluation of a putative noninvasive biomarker of tobacco smoke
exposure - urinary prostaglandin E-metabolite (PGE-M) - in smokers motivated to reduce
and/or cease smoking.
Observational Model: Cohort, Time Perspective: Prospective
Estimate accrual rates and smokers' willingness to provide saliva for cancer risk assessment.
conclusion of study
Jay Boyle, MD
Memorial Sloan-Kettering Cancer Center
United States: Institutional Review Board
|Memorial Sloan Kettering Cancer Center||New York, New York 10021|